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Abstract 
As a means to achieving highly sensitive bioluminescence 
imaging of deep tissues utilizing the firefly luciferin-luciferase 
(L-L) reaction, we previously reported a luciferin analogue, 
AkaLumine, which exhibits high cell-permeability and emits 
near-infrared (NIR) light with high tissue-penetration by the 
L-L reaction. However, while AkaLumine enables us to observe 
targets in deep tissues, its poor solubility in aqueous media 
limits its utility for in vivo imaging. Herein, to address this 
issue, we have synthesized three AkaLumine derivatives with 
N-heterocyclic aromatic rings as new red luciferin analogues 
that have substantially higher solubility than that of AkaLumine 
in phosphate buffered saline solution. One of the derivatives 
(herein termed seMpai) exhibits an emission maximum at 675 
nm upon L-L reaction with Photinus pyralis luciferase and 
presents an activity in mouse-tissue imaging similar to that of 
AkaLumine. It is hoped that seMpai will extend the application 
of high-sensitivity NIR bioluminescence imaging in a wide 
range of biomedical research fields. 
 
Keywords: Bioluminescence, NIR, Deep tissue 
imaging 
 
1. Introduction 
In terms of biological and medical research, in vivo optical 
imaging plays a vital role in the study of biological processes in 
living cells and organs.1,2,3 Firefly bioluminescence is one of 
the most commonly used light sources for fast, safe, and 
non-invasive in vivo optical imaging.4,5 Firefly 
bioluminescence is based on the enzymatic reaction of the 
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substrate firefly luciferin (LH2, Scheme 1) with ATP, Mg2+ and 
O2 in the presence of the firefly luciferase (FLuc). This is 
termed the luciferin-luciferase (L-L) reaction, and it results in a 
yellow-green light emission (bioluminescence emission 
maximum (lBL): 560 nm).6,7 Bioluminescence imaging (BLI) 
using the L-L reaction is performed using a simple instrument 
comprising a photon detector in a dark box. Because the 
technique, unlike fluorescence measurement, does not rely on 
an external light source for excitation, there are no negative 
effects due to the scattering of excitation light. In addition, 
auto-luminescence signals generated by LH2 in living tissues 
are extremely low.8 Thus, BLI provides imaging data with a 
low signal-to-noise ratio. 
In the L-L reaction for BLI, the combination of LH2 and FLuc 
provides highly efficient light emission. However, the 
yellow-green light emitted by the L-L reaction of LH2 with 
FLuc is largely absorbed and easily scattered by biological 
tissues.9,10 To achieve in vivo optical imaging with good 
penetration to deep biological tissues, L-L reactions that 
produce light in the near-infrared (NIR) range (650–900 nm), 
termed the optical window, are required. To obtain NIR light by 
L-L reactions, improved luciferin analogues and mutant 
luciferases have been developed.11,12,13 Luciferin analogues 
containing fused azacycles4 or with conjugated NIR 
fluorophores14 have been developed. Also, Hall et al reported 
NIR (730 and 743 nm) bioluminescence imaging which is the 
combination of the modified naphthyl analogues and the 
mutant luciferase.15 Our group has developed NIR luciferin 
analogues with phenylbutadienyl and biphenyl moieties by 
modification of the p-electronic conjugated structure of 
LH2.16,17 The phenylbutadienyl analogue AkaLumine (1a, 
Scheme 1) shows improved bioluminescence activity with 
FLuc. In order to further tune and improve the luminescence 
properties of 1a, cyclic amino analogues18 and 
allyl-substituted19 analogues of 1a have also been developed. 
The lBL of 1a with FLuc is observed at 675 nm,16 leading to 
more sensitive detection in deep tissues than that achieved with 
LH2.20 However, although 1a represents a breakthrough in the 
development of compounds for deep tissue in vivo optical 
imaging research, it exhibits problematically poor water 
solubility. In fact, the solubility of 1a in phosphate buffered 
saline (PBS) is lower than that of LH2. Thus, in order to expand 
the utility of 1a and its analogues,20 it is necessary to improve 
their water solubilities. One of the possible methods to solve 
this problem is to prepare a salt of 1a with an acid. Accordingly, 
the hydrochloride salt of 1a, termed TokeOni (1a-HCl) was 
found to exhibit good water solubility (30–100 mM in 
water)20,21 and enables the detection of deep targets in the brain 
of mice and marmosets when reacted with mutant luciferase 
AkaLuc, which is specifically optimized for the L-L reaction 
with 1a-HCl.21 As another approach, we planned to introduce a 
hydrophilic moiety into the structure of 1a. Because 
N-heterocycles such as pyridine and pyrazine have water 
solubilities that are generally higher than that of benzene,22 we 
designed the N-aryl analogues 1b–d (Scheme 1). Since 1b–d 
are bioisosteres of 1a, they were reasonably expected to act 
effectively as substrates of firefly luciferase. Herein, we report 
the syntheses, water solubilities, and luminescence properties 
of 1b–d. Of these analogues, 1c shows a bioluminescence 
activity similar to that of 1a. We also investigated cellular and 
animal imaging with 1c together with LH2 and 1a-HCl. 
 
2. Experimental 
2.1. General. Commercially available reagents and solvents 
were used without further purification. AkaLumine (1a) and 
TokeOni (1a-HCl) were provided by Kurogane Kasei Co., Ltd., 
for bioluminescence measurements, and recombinant Ppy 
luciferase (QuantiLum® recombinant luciferase, E1701, 
Promega) was used. Wako Silica gel 70 F254 TLC plates were 
used for analytical TLC, and Kanto Chemical Silica gel 60 N 
(spherical, neutral) were used for column chromatography. For 
preparative flash chromatography, an automated system (Smart 
Flash EPCLC AI-580S, Yamazen Corp., Japan) were used with 
universal columns of silica gel. Melting points were measured 
with a Yanaco MP-500P. IR spectra were obtained with a 
Nicolet 6700 spectrometer with an ATR attachment.1H and 13C 
NMR spectra were recorded on a JEOL ECA-500 instrument 
(500 MHz for 1H and 126 MHz for 13C). High-resolution 
electro-spray ionization mass spectra were obtained with a 
JEOL JMS-T100LC mass spectrometer. The optical purities of 
N-Aryl analogues were analyzed by Daicel’s chiral columns 
screening service (Daicel Chemical Industries, CHIRALPAK® 
IG, 5 µm, 4.6 mm × 150 mm, flow rate 0.8 mL/min). 
UV/visible absorption spectra were obtained using an Agilent 
Technologies Cary 60 spectrophotometer (scan speed 600 
nm/min; data interval 1 nm). Bioluminescence and 
chemiluminescence spectra were measured with an ATTO 
AB-1850 spectrophotometer (data interval 1 nm). 
Bioluminescence intensities were monitored using an ATTO 
AB-2270 and a Microtec Co. GL-201A luminometer. Density 
functional theory (DFT) calculations were performed with the 
Gaussian 09 program (Rev. D.01).23 DFT included the B3LYP 
function with the 6-31+G(d) basis set.24,25,26 Molecular graphics 
were prepared with GaussView, Version 5.27 BLI was 
performed with a multifunctional in vivo imaging system (IVIS 
Spectrum, PerkinElmer). 
 
Scheme 1. Structures of firefly luciferin (LH2), AkaLumine (1a), and the N-aryl analogues 1b–d. 
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2.2. Synthesis of N-aryl analogues 1b–d 
2.2.1. 5-cyano-2-dimethyl amino pyridine (3b). To a solution 
of 2-amino-5-cyianopyridine (2b) (1190 mg, 10.0 mmol) in 
tetrahydrofuran (100 mL), iodomethane (2.83 mL, 45.5 mmol) 
was added and the mixture was stirred at 0 °C. The mixture was 
slowly added sodium hydride (60% in oil, 1440 mg, 36.0 
mmol) and stirred for 12 h. The reaction mixture was added 
methanol (20 mL) to quench the reaction. Further, the reaction 
mixture was added water and extracted with ethyl acetate (3 × 
200 mL). The combined organic layers were dried over Na2SO4, 
filtered, and the solvents were concentrated under reduced 
pressure. The obtained residue was purified by silica gel 
column chromatography (hexane/ethyl acetate = 1/1) to yield 
dimethyl amino 3b (1120 mg, 7.62 mmol, 76%) as a dark 
brown solid: mp 64; IR (neat, n, cm-1): 2213, 1324, 809; 
1H-NMR (500 MHz, CDCl3) d 8.41 (d, J = 2.3 Hz, 1H), 7.59 
(dd, J = 9.2, 2.3 Hz, 1H), 6.48 (d, J = 9.2 Hz, 1H), 3.16 (s, 6H); 
13C-NMR (126 MHz, CDCl3) d 159.7, 152.7, 139.3, 119.1, 
105.1, 95.3, 38.0; HR-ESI-MS: m/z: [M+H]+ calculated for 
C12H10N3, 148.0875; found, 148.0873. 
Dimethyl amino 3c and 3d were prepared with a similar 
procedure to the preparation of 3b. 2-cyiano-5-dimethyl 
amino pyridine (3c) (yield 80%), dark brown solid: mp 65; IR 
(neat, n, cm-1): 2215, 1368, 822; 1H-NMR (500 MHz, CDCl3) d 
8.11 (d, J = 3.4 Hz, 1H), 7.47 (d, J = 9.2 Hz, 1H), 6.88 (dd, J = 
8.9, 3.2 Hz, 1H), 3.09 (s, 6H); 13C-NMR (126 MHz, CDCl3) d 
147.1, 135.4, 129.0, 119.0, 118.9, 116.4, 39.7; HR-ESI-MS: 
m/z: [M+H]+ calculated for C8H10N3, 148.0875; found, 
148.0880. 5-bromo-2-dimethyl amino pyrazine (3d) (yield 
80%), light yellow solid: mp 69; IR (neat, n, cm-1): 2852, 1378, 
998; 1H-NMR (500 MHz, CDCl3) d 8.11 (s, 1H), 7.75 (s, 1H), 
3.10 (s, 6H); 13C-NMR (126 MHz, CDCl3) d 153.9, 143.7, 
129.1, 124.6, 37.8; HR-ESI-MS: m/z: [M+H]+ calculated for 
C6H9N3Br1, 201.9980; found, 201.9990. 
 
2.2.2. 5-aldehyde-2-dimethyl amino pyridine (4b). To a 
solution of dimethyl amino 3b (1120 mg, 7.63 mmol) in dry 
toluene (20 mL) under Ar at 0 °C was slowly added, 1.0 M 
diisobutylaluminium hydride (DIBAL-H) in toluene (12 mL). 
After stirred for 30 min at 0 °C, the mixture was allowed to 
warm to r.t. and stirred 1 h. Then the reaction mixture was 
added acetone (10 mL) to decompose the excess reducing agent. 
Further, the mixed solution was added aqueous sodium 
potassium tartrate (50 mL), ethyl acetate (10 mL) and stirred 
overnight. The mixed solution was extracted with ethyl acetate 
(3 x 100 mL). The combined organic layers were dried over 
Na2SO4, filtered, the solvents were concentrated under reduced 
pressure. The obtained residue was purified by silica gel 
column chromatography (hexane/ethyl acetate = 1/1 to 0/1) to 
yield arylaldehyde 4b (700 mg, 4.67 mmol, 61%) as a 
light-yellow solid: mp 54; IR (neat, n, cm-1): 2709, 1679, 1386, 
815; 1H-NMR (500 MHz, CDCl3) d 9.77 (s, 1H), 8.56 (d, J = 
2.3 Hz, 1H), 7.92 (dd, J = 9.2, 2.3 Hz, 1H), 6.56 (d, J = 8.6 Hz, 
1H), 3.21 (s, 6H); 13C-NMR (126 MHz, CDCl3) d 189.2, 161.4, 
154.6, 136.0, 121.7, 105.7, 38.2; HR-ESI-MS: m/z: [M+H]+ 
calculated for C8H11N2O1, 151.0871; found, 151.0873. 
Arylaldehyde 4c were prepared with a similar procedure to the 
preparation of 4b. 2-aldehyde-5-dimethyl amino pyridine 
(4c) (yield 50%), light yellow solid: mp 69; IR (neat, n, cm-1): 
2787, 1656, 1364, 825; 1H-NMR (500 MHz, CDCl3) d 9.86 (s, 
1H), 8.15 (s, 1H), 7.80 (d, J = 8.6 Hz, 1H), 6.92 (d, J = 9.2 Hz, 
1H), 3.10 (s, 6H); 13C-NMR (126 MHz, CDCl3) d 191.3, 147.9, 
141.2, 133.6, 123.1, 116.2, 39.4; HR-ESI-MS: m/z: [M+H]+ 
calculated for C8H11N2O1, 151.0871; found, 151.0848. 
 
2.2.3. 5-aldehyde-2-dimethyl amino pyridine (4d). To a 
solution of dimethyl amino 3d (1370 mg, 6.82 mmol) in dry 
tetrahydrofuran (50 mL) under Ar at -80 °C was slowly added 
1.57 M n-butyllithium hydride (n-BuLi) in hexane (10.8 mL). 
After stirred for 60 min at -80 °C, the mixture was added 
N,N-dimethylformamide (DMF) (2.0 mL, 26 mmoL) and 
allowed to warm to r.t. After stirred for 1 h, the reaction 
mixture was added water to decompose the excess reducing 
agent. Further, the mixed solution was added water and 
extracted with ethyl acetate (3 x 200 mL). The combined 
organic layers were dried over Na2SO4, filtered, and the 
solvents were concentrated under reduced pressure. The residue 
obtained was purified by silica gel column chromatography 
(hexane/ethyl acetate = 1/1) to yield arylaldehyde 4d (975 mg, 
6.46 mmol, 95%) as a light yellow solid: mp 112; IR (neat, n, 
cm-1): 2783, 1681, 1373, 1008; 1H-NMR (500 MHz, CDCl3) d 
9.91 (s, 1H), 8.69 (s, 1H), 8.08 (d, J = 1.1 Hz, 1H), 3.26 (s, 
6H); 13C-NMR (126 MHz, CDCl3) d 190.7, 155.5, 144.3, 136.8, 
129.4, 37.9; HR-ESI-MS: m/z: [M+H]+ calculated for 
C7H10N3O1, 152.0824; found, 152.0814. 
 
2.2.4. Ethyl 
(2E,4E)-5-(6-(dimethylamino)pyridin-3-yl)penta-2,4-dienoa
te (5b). Sodium hydride (60% in oil, 342 mg, 14.3 mmol) was 
slowly added to a solution of 
5-aldehyde-2-dimethylaminopyridine (4b) (600 mg, 4.00 
mmol) and triethyl 4-phosphonocrotonate (1.5 mL, 12 mmol) 
in dry tetrahydrofuran (50 mL) at 0 °C, and the mixture was 
stirred for 30 min. Ethanol (10 mL) was added to the reaction 
mixture for quenching and the product was extracted with ethyl 
acetate (3 × 50 mL). The combined organic layer was dried 
over Na2SO4, concentrated under reduced pressure. The residue 
was purified by silica gel column chromatography 
(hexane/ethyl acetate = 2/1) to yield ethyl 2,4-pentadienoate 5b 
(433 mg, 1.76 mmol, 44%) as a light-yellow solid: mp 95; IR 
(neat, n, cm-1): 2903, 1704, 1386, 988, 805; 1H-NMR (500 
MHz, CDCl3) d 8.19 (d, J = 2.3 Hz, 1 H), 7.62 (dd, J = 9.2, 2.3 
Hz, 1 H), 7.43 (dd, J = 15.2, 11.2 Hz, 1 H), 6.79 (d, J = 15.5 Hz, 
1 H), 6.66 (dd, J = 15.5, 10.9 Hz, 1 H), 6.51 (d, J = 8.6 Hz, 1 
H), 5.89 (d, J = 15.5 Hz, 1 H), 4.22 (q, J = 7.1 Hz, 2 H), 3.13 (s, 
6 H), 1.31 (t, J = 6.9 Hz, 3 H); 13C-NMR (126 MHz, CDCl3) d 
167.3, 145.5, 144.8, 142.2, 139.7, 134.9, 125.3, 123.7, 120.6, 
117.9, 60.2, 39.9, 14.3; HR-ESI-MS: m/z: [M+H]+ calculated 
for C14H19N2O2, 247.1447; found, 247.1447. 
Ethyl 2,4-pentadienoate 5c and 5d were prepared with a similar 
procedure to the preparation of 5b. Ethyl (2E, 
4E)-5-(5-(dimethylamino)pyridin-2-yl)penta-2,4-dienoate 
(5c) (yield 74%), light yellow solid: mp 105; IR (neat, n, cm-1): 
2898, 1699, 1366, 1004, 815; 1H-NMR (500 MHz, CDCl3) d 
8.14 (d, J = 2.9 Hz, 1 H), 7.47 (dd, J = 15.5, 11.5 Hz, 1 H), 7.23 
(d, J = 8.6 Hz, 1 H), 7.12 (dd, J = 15.2, 11.2 Hz, 1 H), 
6.86–6.92 (m, 2 H), 5.99 (d, J = 14.9 Hz, 1 H), 4.22 (q, J = 7.1 
Hz, 2 H), 3.03 (s, 6 H), 1.31 (t, J = 7.2 Hz, 3 H); 13C-NMR 
(126 MHz, CDCl3) d 167.3, 145.5, 144.8, 142.2, 139.7, 134.9, 
125.3, 123.7, 120.6, 117.9, 60.2, 39.9, 14.3; HR-ESI-MS: m/z: 
[M+H]+ calculated for C14H19N2O2, 247.1447; found, 247.1454. 
Ethyl (2E, 
4E)-5-(5-(dimethylamino)pyrazin-2-yl)penta-2,4-dienoate (5d) 
(yield 65%), light yellow solid: mp 115–118; IR (neat, n, cm-1): 
2942, 1699, 1398, 1006, 876; 1H-NMR (500 MHz, CDCl3) d 
8.05 (m, 2H), 7.46 (dd, J = 15.2, 11.7 Hz, 1 H), 7.14 (dd, J = 
14.9, 11.5 Hz, 1 H), 6.84 (d, J = 15.5 Hz, 1 H), 5.99 (d, J = 15.5 
Hz, 1 H), 4.22 (q, J = 7.1 Hz, 2 H), 3.17 (s, 6 H), 1.31 (t, J = 
7.2 Hz, 3 H); 13C-NMR (126 MHz, CDCl3) d 167.3, 153.8, 
144.5, 142.3, 136.2, 129.9, 125.6, 121.1, 120.6, 60.3, 37.8, 
14.4; HR-ESI-MS: m/z: [M+Na]+ calculated for 
C13H17N3Na1O2, 270.1219; found, 270.1213. 
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2.2.5. (2E, 
4E)-5-(6-(dimethylamino)pyridin-3-yl)penta-2,4-dienoic 
acid (6b). To a solution of ethyl 2,4-pentadienoate 5b (340 mg, 
1.38 mmol) in 2-propanol (50 mL) was added 5 M NaOH aq. 
(560 µL), and the mixture was heated at reflux for 5 h. After 
cooling, the reaction mixture was neutralized by adding 4 M 
HCl aq. and concentrated under reduced pressure. The residue 
was purified by silica gel column chromatography 
(chloroform/methanol = 5/1) to give 2,4-pentadienoic acid 6b
（240 mg, 1.10 mmol, 80%） as a light yellow solid: mp 
215–218; IR (neat, n, cm-1): 1674, 995, 802; 1H-NMR (500 
MHz, CD3OD) d 8.11 (d, J = 2.3 Hz, 1 H), 7.80 (dd, J = 9.2, 
2.3 Hz, 1 H), 7.42 (dd, J = 15.2, 10.0 Hz, 1 H), 6.80–6.89 (m, 2 
H), 6.70 (d, J = 9.2 Hz, 1 H), 5.90 (d, J = 14.9 Hz, 1 H), 3.12 (s, 
6 H); 13C-NMR (126 MHz, CD3OD) d 171.2, 160.1, 149.1, 
147.1, 138.8, 135.9, 124.0, 121.7, 120.4, 107.8, 38.5; 
HR-ESI-MS: m/z: [M+H]+ calculated for C12H15N2O2, 
219.1134; found, 219.1122. 
2,4-pentadienoic acid 6c and 6d were prepared with a similar 
procedure to the preparation of 6b. (2E, 
4E)-5-(5-(dimethylamino)pyridin-2-yl)penta-2,4-dienoic 
acid (6c) (crude 115%), light green solid: mp 230; IR (neat, n, 
cm-1): 3428, 1709, 986, 807; 1H-NMR (500 MHz, DMSO-D6) 
d 8.12 (d, J = 2.9 Hz, 1 H), 7.50 (br, 1 H), 7.35 (dd, J = 14.9, 
11.5 Hz, 1 H), 7.17–7.22 (m, 2 H), 6.99 (d, J = 14.9 Hz, 1 H), 
6.00 (d, J = 15.5 Hz, 1 H), 3.01 (s, 6 H); 13C-NMR (126 MHz, 
CD3OD) d  147.4, 143.4, 139.2, 134.6, 127.5, 124.4, 120.4, 
40.0; HR-ESI-MS m/z: [M+H]+ calculated for C12H15N2O2, 
219.1134; found, 219.1128. (2E, 
4E)-5-(5-(dimethylamino)pyrazin-2-yl)penta-2, 4-dienoic 
acid (6d) (yield 84%), light yellow solid: mp 232; IR (neat, n, 
cm-1): 1674, 1261, 995; 1H-NMR (500 MHz, CD3OD) d 8.11 (s, 
1 H), 8.07 (s, 1 H), 7.28 (dd, J = 15.2, 11.2 Hz, 1 H), 7.12 (dd, 
J = 15.2, 11.2 Hz, 1 H), 6.81 (d, J = 15.5 Hz, 1 H), 6.01 (t, J = 
15.2 Hz, 1 H), 3.16 (s, 6 H); 13C-NMR (126 MHz, CD3OD) d 
174.1, 155.2, 142.9, 138.7, 135.1, 131.0, 127.9, 38.0, 30.8; 
HR-ESI-MS: m/z: [M+H]+ calculated for C11H13N3Na1O2, 
242.0906; found, 242.0908. 
 
2.2.6. Methyl 
N-((2E,4E)-5-(6-(dimethylamino)pyridin-3-yl)penta-2,4-die
noyl)-S-trityl-D-cysteinate (7b). To a solution of 
2,4-pentadienoic acid 6b (126 mg, 0.578 mmol) and 
S-trityl-D-cysteine methyl ester (261 mg, 0.692 mmol) in DMF 
(50 mL), was added 
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDC·HCl) (278 mg, 1.45 mmol) and 
N,N-dimethyl-4-aminopyridine (DMAP) (141 mg, 1.15 mmol), 
and the reaction mixture was stirred for 2 h at r.t. The reaction 
was quenched by adding water (50 mL) and the product was 
extracted with ethyl acetate (3 × 50 mL). The combined organic 
layer was dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The residue was purified by silica gel column 
chromatography (hexane/ethyl acetate =1/1) to yield amide 7b 
(264 mg, 0.457 mmol, 79%) as a light yellow solid: mp 85; IR 
(neat, n, cm-1): 1738, 1651, 1586, 741, 697; 1H-NMR (500 
MHz, CDCl3) d 8.20 (d, J = 2.3 Hz, 1 H), 7.62 (dd, J = 9.2, 2.3 
Hz, 1 H), 7.20–7.39 (m, 17 H), 6.77 (d, J = 15.5 Hz, 1 H), 6.65 
(dd, J = 15.2, 11.2 Hz, 1 H), 6.51 (d, J = 9.2 Hz, 1 H), 5.95 (d, 
J = 8.0 Hz, 1 H), 5.84 (d, J = 14.9 Hz, 1 H), 4.74 (dd, J = 12.6, 
5.2 Hz, 1 H), 3.72 (s, 3 H), 3.13 (s, 6 H), 2.70 (t, J = 4.6 Hz, 2 
H); 13C-NMR (126 MHz, CDCl3) d 171.1, 165.9, 158.8, 148.4, 
144.3, 142.3, 137.0, 134.2, 129.4, 127.9, 126.79, 122.4, 121.0, 
120.1, 105.8, 66.8, 52.5, 51.3, 38.0, 33.9; HR-ESI-MS: m/z: 
[M+H]+ calculated for C35H36N3O3S1, 578.2477; found, 
578.2491. 
Amide 7c and 7d were prepared with a similar procedure to the 
preparation of 7b. Methyl 
N-((2E,4E)-5-(5-(dimethylamino)pyridin-2-yl)penta-2,4-die
noyl)-S-trityl-D-cysteinate (7c) (yield 79%), light yellow 
solid: mp 86; IR (neat, n, cm-1): 1738, 1651, 1575, 741, 697; 
1H-NMR (500 MHz, CDCl3) d 8.15 (d, J = 2.9 Hz, 1 H), 
7.21–7.39 (m, 16 H), 7.13 (dd, J = 14.9, 11.5 Hz, 1 H), 6.92 (dd, 
J = 8.9, 3.2 Hz, 1 H), 6.85 (d, J = 15.5 Hz, 1 H), 5.90–5.94 (m, 
2 H), 4.74 (dd, J = 12.9, 5.4 Hz, 1 H), 3.73 (s, 3 H), 3.03 (s, 6 
H), 2.74 (q, J = 6.1 Hz, 1 H), 2.68 (dd, J = 12.3, 4.9 Hz, 1 H); 
13C-NMR (126 MHz, CDCl3) d 171.0, 165.6, 145.4, 144.3, 
142.5, 142.1, 139.0, 134.9, 129.5, 128.0, 126.9, 125.4, 123.7, 
122.5, 118.0, 67.0, 52.7, 51.1, 40.0, 34.0; HR-ESI-MS: m/z: 
[M+H]+ calculated for C35H36N3O3S1, 578.2477; found, 
578.2478. Methyl 
N-((2E,4E)-5-(5-(dimethylamino)pyrazin-2-yl)penta-2,4-die
noyl)-S-trityl-D-cysteinate (7d) (yield 84%), light yellow 
solid: mp 70; IR (neat, n, cm-1): 1738, 1651, 1569, 741, 697; 
1H-NMR (500 MHz, CDCl3) d 8.05 (s, 2 H), 7.20–7.44 (m, 15 
H), 7.13 (dd, J = 14.9, 11.5 Hz, 1 H), 6.82 (d, J = 14.9 Hz, 1 H), 
5.93 (m, 2 H), 4.74 (d, J = 8.0 Hz, 1 H), 3.73 (s, 3 H), 3.18 (s, 6 
H), 2.67–2.73 (m, 2 H); 13C-NMR (126 MHz, CDCl3) d 171.0, 
165.6, 153.8, 144.3, 142.2, 141.8, 137.3, 135.6, 129.8, 129.6, 
129.5, 128.0, 128.0, 126.9, 126.8, 125.6, 122.9, 67.0, 52.7, 51.2, 
37.8, 34.0; HR-ESI-MS: m/z: [M+H]+ calculated for 
C34H34N4Na1O3S1, 601.2249; found, 601.2243. 
 
2.2.7. Methyl 
(S)-2-((1E,3E)-4-(6-(dimethylamino)pyridin-3-yl)buta-1,3-di
en-1-yl)-4,5-dihydrothiazole-4-carboxylate (8b). To a 
solution of amide 7b (191 mg, 0.331 mmol) in dichloromethane 
(10 mL) was added trifluoromethanesulfonic anhydride (Tf2O) 
(170 µL, 1.00 mmol) under Ar at 0 °C and the mixture was 
stirred for 10 min. Ion exchange resin IRA400 OH AG was 
added to the reaction mixture for neutralization. The resin was 
filtered through a cotton plug and washed thoroughly with 
methanol. The filtrate was concentrated in vacuo. The crude 
products were purified by PTLC (hexane/ethyl acetate = 2/1) to 
yield thiazolidine ester 8b (51.6 mg, 0.163 mmol, 48%) as 
yellow solid: mp 134; IR (neat, n, cm-1): 2914, 1746, 1588, 
1201,994, 799; 1 H-NMR (500 MHz, CDCl3) d 8.17 (d, J = 2.3 
Hz, 1 H), 7.64 (dd, J = 9.2, 2.3 Hz, 1 H), 6.93 (dd, J = 15.5, 9.7 
Hz, 1 H), 6.68–6.75 (m, 2 H), 6.50–6.56 (m, 2 H), 5.17 (t, J = 
8.9 Hz, 1 H), 3.83 (s, 3 H), 3.59 (dd, J = 11.5, 9.2 Hz, 1 H), 
3.53 (dd, J = 10.9, 9.2 Hz, 1 H), 3.13 (s, 6 H); 13C-NMR (126 
MHz, CDCl3) d 171.4, 170.2, 159.0, 148.8, 143.3, 136.3, 134.1, 
123.3, 123.1, 120.2, 105.9, 77.9, 52.8, 38.1, 34.6; HR-ESI-MS: 
m/z: [M+H]+ calculated for C16H20N3O2S1, 318.1276; found, 
318.1271. 
Thiazolidine-ester 8c and 8d were prepared with a similar 
procedure to the preparation of 8b. Methyl 
(S)-2-((1E,3E)-4-(5-(dimethylamino)pyridin-2-yl)buta-1,3-di
en-1-yl)-4,5-dihydrothiazole-4-carboxylate (8c) (yield 63%), 
brown solid: mp 117; IR (neat, n, cm-1): 2949, 1725, 1576, 
1206, 987; 1H-NMR (500 MHz, CDCl3) d 8.14 (d, J = 3.4 Hz, 1 
H), 7.22 (d, J = 8.6 Hz, 1 H), 7.15 (dd, J = 14.9, 10.9 Hz, 1 H), 
6.90–6.99 (m, 2 H), 6.81 (d, J = 15.5 Hz, 1 H), 6.65 (d, J = 15.5 
Hz, 1 H), 5.17 (t, J = 9.2 Hz, 1 H), 3.83 (s, 3 H), 3.61 (t, J = 
10.0 Hz, 1 H), 3.54 (t, J = 10.0 Hz, 1 H), 3.03 (s, 6 H); 
13C-NMR (126 MHz, CDCl3) d 171.4, 170.1, 145.4, 142.8, 
142.5, 138.0, 134.9, 126.2, 125.0, 123.6, 118.0, 77.9, 52.8, 40.0, 
34.5; HR-ESI-MS: m/z: [M+H]+ calculated for C16H20N3O2S1, 
318.1276; found, 318.1271. Methyl 
(S)-2-((1E,3E)-4-(5-(dimethylamino)pyrazin-2-yl)buta-1,3-d
ien-1-yl)-4,5-dihydrothiazole-4-carboxylate (8d) (yield 44%) 
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yellow solid: mp 142; IR (neat, n, cm-1): 2940, 1745, 1574, 
1197, 982; 1H-NMR (500 MHz, CDCl3) d 8.04 (s, 2 H), 
7.14–7.20 (m, 1 H), 6.94–6.99 (m, 1 H), 6.77 (d, J = 14.9 Hz, 1 
H), 6.65 (d, J = 15.5 Hz, 1 H), 5.17 (t, J = 8.9 Hz, 1 H), 3.83 (s, 
3 H), 3.54–3.63 (m, 2 H), 3.17 (s, 6 H); 13C-NMR (126 MHz, 
CDCl3) d 171.3, 170.0, 153.7, 142.5, 142.2, 137.3, 134.5, 129.9, 
126.4, 125.3, 78.0, 52.8, 37.8, 34.6; HR-ESI-MS: m/z: [M+H]+ 
calculated for C15H19N4O2S1, 319.1229; found, 319.1230. 
 
2.2.8. 
(S)-2-((1E,3E)-4-(6-(dimethylamino)pyridin-3-yl)buta-1,3-di
en-1-yl)-4,5-dihydrothiazole-4-carboxylic acid (1b). A 
solution of thiazolidine ester 8b (147 mg, 0.463 mmol) in 6 M 
HCl aq. (30 mL) was stirred at r.t. for 18 h. After the reaction 
mixture was added sodium bicarbonate to neutralize, the 
mixture was concentrated under reduced pressure. The crude 
products were purified by automated flash chromatography 
system (Smart Flash EPCLC AI-580S, ULTRAPACK 
COLUMNS C18, H2O/ methanol = 9/1 to 1/9) to yield N-aryl 
luciferin analogue 1b (101 mg, 0.332 mmol, 72 %) as an 
orange solid: mp 258–261; IR (neat, n, cm-1): 3360, 1589, 983; 
1H-NMR (500 MHz, DMSO-D6) d 8.17 (d, J = 2.3 Hz, 1 H), 
7.78 (dd, J = 8.6, 2.3 Hz, 1 H), 6.74–6.92 (m, 3 H), 6.67 (d, J = 
9.2 Hz, 1 H), 6.52 (d, J = 14.9 Hz, 1 H), 4.71 (t, J = 8.9 Hz, 1 
H), 3.49 (dd, J = 10.3, 9.2 Hz, 1 H), 3.30–3.41 (m, 1 H), 3.06 (s, 
6 H); 13C-NMR (126 MHz, DMSO-D6) d 172.0, 163.1, 158.6, 
148.1, 140.7, 134.8, 134.2, 124.5, 123.5, 120.2, 106.0, 83.2, 
37.7, 35.4; HR-ESI-MS: m/z: [M+H]+ calculated for 
C15H18N3O2S1, 304.1120; found, 304.1100; 90%e.e. from chiral 
HPLC (retention time of L-isomer: 8.60 min, D-isomer: 20.2 
min, Formic acid buffer at pH 2.0/methanol = 10/90, detection 
of UV: 360 nm). 
N-aryl luciferin analogue 1c and 1d were prepared with a 
similar procedure to the preparation of 1b. 
(S)-2-((1E,3E)-4-(5-(dimethylamino)pyridin-2-yl)buta-1,3-di
en-1-yl)-4,5-dihydrothiazole-4-carboxylic acid (1c) (yield 
63%) yellow solid: mp 207; IR (neat, n, cm-1): 3207, 1575, 
984; 1H-NMR (500 MHz, DMSO-D6) d 8.12 (d, J = 3.4 Hz, 1 
H), 7.33 (d, J = 8.6 Hz, 1 H), 7.15 (dd, J = 15.5, 10.9 Hz, 1 H), 
7.05 (dd, J = 8.6, 2.9 Hz, 1 H), 6.80–6.88 (m, 2 H), 6.62 (d, J = 
14.9 Hz, 1 H), 4.76 (t, J = 8.9 Hz, 1 H), 3.50 (t, J = 9.5 Hz, 1 
H), 3.33–3.37 (m, 1 H), 2.98 (s, 6 H); 13C-NMR (126 MHz, 
DMSO-D6) d 171.7, 163.3, 145.3, 142.1, 140.2, 137.0, 134.7, 
126.0, 125.9, 123.2, 118.1, 82.9, 39.2, 35.4; HR-ESI-MS: m/z: 
[M+H]+ calculated for C15H18N3O2S1, 304.1120; found, 
304.1107; 90%e.e. from chiral HPLC (retention time of 
L-isomer: 12.1 min, D-isomer: 15.5 min, Formic acid buffer at 
pH 2.0/methanol = 10/90, detection of UV: 400 nm). 
(S)-2-((1E,3E)-4-(5-(dimethylamino)pyrazin-2-yl)buta-1,3-d
ien-1-yl)-4,5-dihydrothiazole-4-carboxylic acid (1d) (yield 
37%) yellow solid: mp 204–207; IR (neat, n, cm-1): 3234, 1568, 
1386, 982; 1H-NMR (500 MHz, CD3OD) d 8.13 (s, 1 H), 8.09 
(s, 1 H), 7.18 (dd, J = 15.2, 11.2 Hz, 1 H), 7.04 (dd, J = 15.5, 
10.9 Hz, 1 H), 6.86 (d, J = 15.5 Hz, 1 H), 6.61 (d, J = 14.9 Hz, 
1 H), 5.06 (t, J = 8.9 Hz, 1 H), 3.59 (m, 2 H), 3.17 (s, 6 H); 
13C-NMR (126 MHz, CD3OD) d 176.2, 171.9, 155.4, 144.1, 
143.4, 138.5, 136.2, 131.3, 127.7, 125.7, 80.3, 38.1, 36.4; 
HR-ESI-MS: m/z: [M+H]+ calculated for C14H17N4O2S1, 
305.1072; found, 305.1077; 87%e.e. from chiral HPLC 
(retention time of L-isomer: 19.6 min, D-isomer: 26.5 min, 0.1 
M Potassium hexafluorophosphate buffer at pH 2.0/ acetonitrile 
= 65/35, detection of UV: 450 nm). 
 
2.3. Measurement of solubility in PBS. The solubility of each 
compound in PBS (1×, pH 7.4, gibco® by lifetechnologies™) 
at 25 °C was determined by UV/vis absorption measurement. 
Molar extinction coefficients (e) of 1a–d in PBS were initially 
determined (Table 1 and Figure S1). Then, a saturated solution 
of each compound was prepared at 25 °C and absorbance of an 
appropriately diluted solution of the saturated one was 
measured to give the maximum concentration (cmax). 
 
2.4. Luminescence measurements 
2.4.1. Measurement of bioluminescence activity. The 
bioluminescence activities of 1b–d together with those of LH2 
and 1a16 were investigated using Ppy luciferase. The substrates 
were dissolved in 50 mM KPB (pH 6.0), Ppy luciferase was 
dissolved in 50 mM KPB (pH 8.0) containing 10% glycerol, 
and Mg-ATP was dissolved in ultrapure water. An L-L reaction 
was initiated by injection of 10 µL of Mg-ATP (200 µM) into a 
mixture of 5 µL of a substrate solution (100 µM), 5 µL of 
luciferase solution (1 mg/mL), and 5 µL of KPB (500 mM, pH 
8.0). Light emission was monitored in the range 400–750 nm in 
increments of 1 nm for 180 s to provide emission spectra. Light 
intensity was determined as the intensity of the emission 
spectrum at the lBL value. 
 
2.4.2. Measurement of Km and Vmax values. For 
Lineweaver-Burk analysis, the light emission from an L-L 
reaction was monitored with the ATTO AB-2270 luminometer 
for 30 s with sampling intervals of 0.1 s. Emission intensities 
were expressed as counts per second (cps). The L-L reaction 
was initiated by injecting 40 µL of Mg-ATP (200 µM) into a 
mixture of 20 µL of a substrate solution (100 µM) 20 µL 
luciferase solution (0.1 mg/mL), and 20 µL KPB (500 mM, pH 
8.0) at room temperature. The substrates were dissolved in 50 
mM KPB (pH 6.0), Ppy luciferase (1mg/mL in 50 mM KPB 
containing 10% glycerol, pH 8.0) was dissolved to 0.1 mg/mL 
by 50 mM KPB (pH 6.0) containing 35% glycerol, and 
Mg-ATP was dissolved in ultrapure water. The final 
concentrations of the substrates were varied from 0.02 to 100 
µM. The Km and Vmax values of the substrates were determined 
from the integrated values of emission intensities and 
calculated using Lineweaver-Burk plots with the Enzyme 
Kinetics Wizard module in the commercially available 
SigmaPlot 13.0 software package (Systat Software Inc.). 
 
2.4.3. Measurement of chemiluminescence activity. 
Analogues 1b–d were treated with propylphosphonic anhydride 
(T3P) and triethylamine (NEt3) according to a previously 
published protocol.28 A chemiluminescence reaction was 
initiated by injecting 150 µL T3P (150 mM) in DMF into a 
mixture of 40 µL of a substrate (20 mM) in DMF and 40 µL 
NEt3 (500 mM) in DMF. Chemiluminescence spectra of the 
substrates were measured with the ATTO AB-1850 
spectrophotometer in the range 400–750 nm in increments of 1 
nm for 180 s. 
 
2.5. Cell and animal imaging 
2.5.1. Cell culture. The murine Lewis lung carcinoma cell line 
LLC was obtained from ATCC (Rockville, MD, USA). 
LLC/luc was established with a luc+ gene as previously 
described.20 LLC/mKO2-Rluc8.6 were established as 
previously described.20,29 The cells were maintained at 37 °C in 
Dulbecco's modified essential medium (Nacalai Tesque) 
supplemented with 5% fetal calf serum, penicillin (100 
units/mL), and streptomycin (100 µg/mL) and regularly 
checked for mycoplasma contamination using a mycoplasma 
check kit (Lonza). 
 
2.5.2. Cellular imaging. The substrates were reacted with 
LLC/luc (2 × 105 cells/well) in a black 96-well plate. 
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Bioluminescence was measured using IVIS Spectrum 1 min 
after adding the substrates. The following conditions were used 
for image acquisition: open (for total bioluminescence) or 680 
± 10 nm using an emission filter (for NIR bioluminescence), 
exposure time = 10 s, binning = medium: 8, field of view = 
12.9 × 12.9 cm, and f/stop = 1. The bioluminescence images 
were analyzed using Living Image 4.3 software (PerkinElmer) 
specialized for IVIS. 
 
2.5.3. Cell viability assay. LLC/mKO2-Rluc8.6 cells (2 × 104 
cells/well) were seeded into a 24-well plate. After 24-h 
incubation, the cells were further cultured for 24-h with the 
substrate at the indicated concentration. Then, the cells in each 
well were harvested to prepare cell lysates and their Rluc 
bioluminescence activity was measured using a GL-201A 
luminometer. 
 
2.5.4. Mice. C57B/6 albino mice (female and male, six weeks 
old) were obtained from Charles River Laboratory Japan 
(Yokohama, Japan). All the experimental procedures using 
mice have been previously approved by the Animal Experiment 
Committees of the Tokyo Institute of Technology (authorization 
number 2014005) and carried out in accordance with the 
relevant national and international guidelines. 
 
2.5.5. Tumor models. For subcutaneous tumor models, 
LLC/luc (3 × 105 cells/10 µL) suspended in PBS was mixed 
with an equal volume of Geltrex® (Invitrogen, Thermo Fisher 
Scientific) and subcutaneously injected into C57B/6 albino 
mice (female). The experiments were performed 4 days after 
injection. For the lung metastasis model, LLC/luc (5 × 105 
cells/100 µL) suspended in PBS was injected into the tail vein 
of C57B/6 albino mice (male). The experiments were 
performed 10–20 days after intravenous injection. 
 
2.5.6. Animal imaging. Bioluminescence images of 
subcutaneous tumors and lung metastasis were sequentially 
acquired with IVIS Spectrum every 3 min for 30 min after 
intraperitoneal injection with 100 µL of 33 mM substrates, and 
the highest bioluminescence intensities among the acquired 
images were selected for analysis. For comparing 
bioluminescence production between different substrates using 
the same mice, the images for analogue 1c were acquired 4-h 
after injection of LH2, in which the effect of LH2 had 
completely disappeared.20 The following conditions were used 
for image acquisition: open emission filter, exposure time = 60 
s, binning = medium: 8, field of view = 12.9 × 12.9 cm, and 
f/stop = 1. The bioluminescence images were analyzed using 
Living Image 4.3 software (PerkinElmer) specialized for IVIS. 
 
2.5.7. Statistical analysis. Data are presented as means ± 
standard error of the mean and were statistically analyzed with 
a two-side Student’s t-test. P values of less than 0.05 were 
considered statistically significant. 
 
3. Results and Discussion 
3.1. Synthesis of N-aryl analogues of AkaLumine. The 
analogues 1b, 1c, and 1d, which have a pyridine or pyrazine 
ring in place of the benzene ring of 1a (Scheme 1), were 
designed to have superior aqueous solubilities to that of 1a 
while maintaining its bioluminescence activity. The N-aryl 
analogues 1b–d were synthesized by a procedure similar to that 
for 1a (Scheme 2). As key synthetic intermediates, 
arylaldehydes 4b–d were prepared from the corresponding 
commercially available aminonitriles and aminobromide. 
Arylaldehydes 4b and 4c were prepared by dimethylation of 
aminonitriles followed by DIBAL-H reduction. Arylaldehyde 
4d was prepared by dimethylation of 
5-bromo-2-pyrazinecarbonitrile followed by formylation via 
the lithiated anion. Horner-Wadsworth-Emmons reactions of 
4b–d with triethyl 4-phosphonocrotonate afforded 
5-aryl-2,4-pentadienoates 5b–d, which were hydrolyzed to give 
carboxylic acids 6b–d. Condensations of 6b–d with 
S-trityl-D-cysteine methyl ester gave amides 7b–d, and the 
following thiazole ring formations with Tf2O afforded esters 
8b–d. Finally, acid hydrolysis of 8b–d produced the target 
analogues 1b–d. 
 
3.2. Water solubilities of 1b–d. The maximum concentrations 
(cmax) of 1b, 1c, and 1d in PBS at pH 7.4 and 25 °C were 
determined to be 28, 69, and 480 mM, respectively (Table 1). 
Thus, the cmax values of 1b–d are greater than that of 1a (2.2 
mM) (Table 1), indicating substituting the benzene ring in the 
structure of 1a with a pyridine or pyrazine ring is an effective 
means of improving water solubility. Clearly, the pyrazine 
analogue 1d has the highest water solubility among the N-aryl 
analogues. Interestingly, the 2-pyridyl analogue 1c exhibits 
superior water solubility to that of the 3-pyridyl analogue 1b, 
despite 1b and 1c differing only in the position of the pyridyl 
nitrogen. 
 
 
Table 1. Electronic absorption properties and water solubilities 
of 1a–d in PBS (1×, pH 7.4) at 25 °C 
 
Compound lmax/nm  (e /105 dm3 mol−1 cm−1)a cmax
b /mM 
1a 370 (2.2) 2.2 
1b 375 (2.1) 28 
1c 375 (1.6) 69 
1d 390 (1.4) 480 
 
aAbsorption maximum of the lowest-energy absorption band 
(lmax). Molar extinction coefficient (e) given in parentheses. 
bThe maximum concentrations (cmax) in PBS (pH 7.4) at 25 °C. 
 
 
3.3. Luminescence properties of 1b–d. Since the luciferase of 
the North American firefly Photinus pyralis (Ppy) is commonly 
used in the L-L reaction for BLI, we investigated the 
bioluminescence activity with Ppy luciferase. The L-L 
reactions with Ppy luciferase of 1b–d together with those of 
LH2 and 1a in potassium phosphate buffer (KPB) at pH 8.0 in 
the presence of ATP and Mg2+ under air were investigated. The 
bioluminescence properties of 1a–d and LH2 are summarized 
in Table 2. 1b–d show moderate luminescence activities. The 
light intensities (Rel. Int.) during the initial 180 s for 1a–d are 
36%, 135%, 10%, and 4%, respectively, as relative values 
compared with that of LH2 (Table 2), indicating that 1b–d have 
moderate luminescence activities. Emission maxima (lBL) in 
the bioluminescence spectra of 1b, 1c, and 1d are observed at 
640, 675, and 625 nm, respectively (Figure 1A and Table 2). 
Thus, the lBL values of all the new analogues are red-shifted 
compared to that of LH2. The lBL values for 1b and 1d are 
blue-shifted by 35 and 50 nm, respectively, compared to that of 
1a, while 1c exhibits a similar lBL value to that of 1a (Figure 
1A and Table 2). To investigate the cause of the variation in lBL 
 
 
Scheme 2. Synthesis route to N-aryl luciferin analogues 1b, 1c and 1d. a) CH3I, NaH, 0 °C; b) DIBAL-H, 0 °C; c) n-BuLi, -80 °C 
then DMF, r.t.; d) Triethyl 4-phosphonocrotonate, NaH, 0 °C; e) NaOH aq, reflux; f) EDC, DMAP, D-H-Cys(Trt)-OMe, r.t.; 
g)Tf2O, 0 °C; h) HCl aq, r.t. 
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values for 1b–d, chemiluminescence reactions of 1a–d were 
performed in DMF containing T3P and NEt3 under air.28 The 
chemiluminescence emission maxima (lCL) of 1a–d are 
observed at 645, 600, 635, and 595 nm, respectively (Figure 1B 
and Table 2). Much like the variation in the lBL values of 1b–d, 
1b and 1d exhibit 45 and 50 nm blue-shifted lCL values, 
respectively, compared with that of 1a, and the lCL value of 1c 
is slightly blue-shifted (Figure 1B and Table 2). These results 
indicate that the lBL and lCL values of 1b–d are largely 
determined by their p-electronic properties. 
 
 
 
 
 
 
 
 
Table 2. Bio- and chemiluminescence properties of LH2 and  
1a–d 
Compound Rel. Inta lBL
b 
/nm 
lCLc 
/nm Km /µM 
Rel. 
Vmaxd 
LH2 100% 560 620 107 ± 15e – 
1a 36% 675 645 1.3 ± 0.3 100% 
1b 135% 640 600 29 ± 5 240% 
1c 10% 675 635 6.2 ± 1.2 180% 
1d 4% 625 595 57 ± 9 6.5% 
 
aRelative light intensities at lBL for the L-L reactions of 1a–d 
during the initial 180 s compared to that of LH2. 
bBioluminesnce emission maximum. 
cChemiluminesnce emission maximum. 
dRelative Vmax during the initial 30 s for the L-L reactions of 
1b–d compared to that of 1a. The concentration of Mg-ATP 
was 200 µM in H2O. 
eRef.20 
 
Figure 1. Emission spectra of bioluminescence (A) and 
chemiluminescence (B) of LH2 and 1a–d. 
 
The kinetic constants (Km and Rel. Vmax) for 1a–d were 
investigated by the previously reported method.20 The Km 
values of 1a–d are 1.3, 29, 6.2, and 57 µM, respectively (Table 
2). Thus, the Km values of 1b–d are greater than that of 1a. This 
result corresponds with the observation that the water 
solubilities of 1b–d are better than that of 1a. In fact, the 
pyrazine-containing analogue 1d has the largest Km value 
among 1a–d. Thus, the hydrophilicity of 1d decreases its 
affinity with the luciferase active site. Interestingly, the Km 
value of 1b is approximately five-fold that of 1c, indicating that 
the position of the N atom has a profound effect on affinity 
with the luciferase active site. The pyridine-containing 
analogues 1b and 1c exhibit greater Rel. Vmax values than that 
of 1a, and the pyrazine-containing analogue 1d exhibits a 
smaller Rel. Vmax value than that of 1a. Because the Rel. Vmax 
value reflects the bioluminescence quantum yield (FBL) and 
rate constant of the enzymatic reaction (kcat), the N atom in the 
N-aryl moieties affects interactions with the luciferase active 
site, thus largely determining the FBL and kcat values. 
 
 
3.4. Density functional theory calculations for the light 
emitters generated from the bio- and chemiluminescence 
reactions of 1a–d. Oxyluciferin (OLH) is the light emitter in 
the L-L reaction of LH2. While OLH in the ground state has the 
enol form as the most stable structure,30,31 the excited state of 
OLH generated by the L-L reaction of LH2 adopts the 
keto-phenolate form.6,7,32 Thus, it is reasonable to assume that 
the keto forms of oxy-1a–d (Figure 2A) are the light emitters in 
the L-L reactions of 1a–d.18 To further investigate the observed 
lBL and lCL values for 1b–d, the electronic properties of 
oxy-1b–d were investigated by density functional theory (DFT) 
and time-dependent DFT (TD-DFT) calculations with the 
B3LYP/6-31+G(d) method. The optimized structures of 
oxy-1b–d together with that of oxy-1a18 are shown in Figure 2A 
and the calculation data are summarized in Table 3, which 
shows the energy levels of the HOMOs and LUMOs, the 
HOMO-LUMO energy gaps (DEH−L), and the wavelengths (ltr), 
oscillator strengths (f), and configurations for the S0 → S1 
transitions in oxy-1a–d. 
 
The electronic distributions for the HOMOs and LUMOs of 
oxy-1b–d are similar to those for oxy-1a. The HOMO and 
LUMO levels of oxy-1b–d are slightly lower than those of 
oxy-1a because oxy-1b–d contains an N-heterocycle instead of 
the benzene ring in oxy-1a. The DEH−L values of oxy-1b–d are 
slightly higher than that of oxy-1a. The order of DEH−L values 
(oxy-1a < oxy-1c < oxy-1b < oxy-1d) roughly corresponds to 
those of the lBL values (oxy-1a ≈ oxy-1c > oxy-1b > oxy-1d) 
and lCL values (oxy-1a > oxy-1c > oxy-1b > oxy-1d), indicating 
that the emission maximum wavelengths of bioluminescence 
and chemiluminescence for 1a–d are mainly determined by the 
electronic properties of oxy-1a–d. Interestingly, however, the 
lBL values of 1a and 1c are similar, indicating that the 
emissions of the lowest excited singlet (S1) states of oxy-1a–d 
generated by the L-L reactions are modulated by interactions 
with the luciferase active site. 
 
Table 3. DFT and TD-DFT calculation data for oxy-1a–d 
Compound 
HOMO 
/eV 
LUMO 
/eV 
DEH−La 
/eV 
ltr/nm 
(f) b 
Configurationc 
 
Figure 2. Optimized structures of oxy-1a–d (A) and their HOMOs and LUMOs (B). The data of oxy-1a were reproduced using 
the reported ones in Ref. 18. 
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oxy-1ad −5.54 −2.65 2.89 
439 
(1.38) 
H → L  
(0.70) 
oxy-1b −5.76 −2.77 2.99 
426 
(1.43) 
H → L  
(0.70) 
oxy-1c −5.70 −2.74 2.96 
432 
(1.29) 
H → L 
 (0.70) 
oxy-1d −5.91 −2.87 3.03 
421 
(1.37) 
H → L  
(0.70) 
aEnergy difference between HOMO and LUMO. 
bWavelength estimated from the energy of the S0 → S1 
transition. Oscillator strengths (f) are in the parentheses. 
cConfiguration of excitation. Coefficients are in the parentheses. 
H and L denote HOMO and LUMO, respectively. 
dRef.18 
 
 
The HOMOs of oxy-1a–d exhibit electronic distribution mainly 
at the (4-dimethylaminophenyl)-ethenyl moiety, and their 
LUMOs exhibit electronic distributions mainly at the 
2-butadinenyl-1,3-thiazolone moiety (Figure 2B). Thus, 
electronic excitations in oxy-1b–d due to HOMO-LUMO 
transitions have charge-transfer characteristics, producing 
polarized excited singlet states. The electronic properties of the 
HOMOs and LUMOs of oxy-1a–d result in their large f values 
(over 1.2) for transitions from the ground (S0) states to the 
lowest excited singlet (S1) states (Table 3). Because the 
fluorescence emission process is the reverse process of the S0 
→ S1 transition, a rate constant of fluorescence emission is 
predicted from the f value of the S0 → S1 transition.33 Thus, the 
f values for oxy-1a–d indicate that they are good light emitters. 
 
 
3.5. Cellular imaging. For cellular and animal imaging 
experiments, we choose 1c as a preferential N-aryl analogue, 
because the lBL value of 1c is almost same as that of 1a. In fact, 
it is known that a longer lBL value is more effective to improve 
a BL image in a deep animal tissue than a higher BL intensity.20 
At first, we investigated bioluminescence property of 1c in 
culture cells together with that of 1a. For the purpose, we 
treated murine Lewis lung carcinoma (LLC) constitutively 
expressing FLuc (LLC/luc) with various concentrations of LH2, 
1a-HCl and 1c (Figure 3A). Cells treated with 1c emit robust 
NIR bioluminescence comparable with those treated with 
1a-HCl. Furthermore, 1c exhibits higher cellular 
bioluminescence production than that of LH2 at lower 
concentrations (Figure 3A). The ability of 1c to produce intense 
NIR bioluminescence, even at low concentrations, is similar to 
that of 1a-HCl20,21 and is beneficial because repetitive 
injections of large amounts of substrate, which is often required 
in animal imaging, can be avoided, decreasing the risk to 
animal health. As reported by Yeh et al.,34 1a-HCl decreases the 
cell viability at higher concentrations (> 500 µM). On the other 
hand, 1c does not affect the cell viability even at high 
concentrations (Figure 3B). Although toxicity of 1a-HCl has 
not been observed in animal experiments so far,21 the 
improvement of the solubility and cytotoxicity in 1c can 
remove the potential problems of 1a-HCl in animal 
experiments. Considerations on its toxicity are described in the 
Supporting Information (Section S3). 
 
Figure 3. Cellular imaging. (A) Bioluminescence production in 
LLC/luc cells treated with different concentrations of the 
indicated substrates. Total (left) and NIR (right) 
bioluminescence were obtained with open filter or NIR filter 
(680±10 nm), respectively. n=3, *P<0.05. (B) Viability of 
LLC/luc cells treated with different concentrations of the 
indicated substrates. n=3, *P<0.05. 
 
 
3.6. Animal imaging. The bioluminescence of 1c are compared 
with that of LH2 and 1a-HCl in mouse tumor models. First, the 
bioluminescence signals from LH2 and 1c at subcutaneous 
tumors located near the body surface of mice were compared 
for the same dose. A slightly higher signal is detected from 
1c-injected mice compared to that from the LH2-injected ones 
(Figure 4A). Thus, the benefit of using 1c for bioluminescence 
imaging in subcutaneous tumors near the surface of the body is 
not significant. However, when we next compared the 
bioluminescence signals in lung metastasis, in which the targets 
are located deep inside the body, the NIR bioluminescence of 
1c improves the detection sensitivity for targets in deep tissues, 
exhibiting a six-fold increase in bioluminescence intensity 
compared to that of LH2 (Figure 4B). In addition, 1c exhibits a 
comparable sensitivity to that of 1a-HCl in the imaging of lung 
metastases (Figure 4C). These results indicate that 1c is a 
suitable substrate for bioluminescence imaging of deep tissues 
in small animals. 
 
Figure 4. Animal imaging. (A) Bioluminescence production in 
subcutaneous LLC/luc tumors after injection with 33 mM LH2 
or 1c. n = 6. (B) Bioluminescence production in LLC/luc lung 
metastases after injection with 33 mM LH2 or 1c. n = 6, *P < 
0.05. (C) Bioluminescence production in LLC/luc lung 
metastases after injection with 33 mM 1c or 1a-HCl. n = 3. 
 
 
4. Conclusion 
We synthesized the N-aryl luciferin analogues 1b–d, which 
were designed based on the NIR luciferin analogue 1a 
(AkaLumine) for improved water solubility. As expected, 1b–d 
exhibit higher solubility than that of 1a in PBS. Specifically, 1d 
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has the highest solubility among 1a–d. Analogues 1b–d exhibit 
moderate luminescence activities in L-L reactions with FLuc in 
KPB at pH 8.0. The lBL values for 1b–d are presented in the 
red-NIR region, and 1c exhibits a lBL value similar to that of 1a. 
The lBL values of 1a–d show a similar trend to that of the lCL 
values observed in DMF. DFT and TD-DFT calculation results 
indicate that these variations in the lBL and lCL values are 
largely determined by the electronic properties of the 
oxyluciferin analogues corresponding to 1a–d. Because the 
water solubilities of 1b–d are better than that of 1a, the Km 
values of 1b–d are higher than that of 1a. Interestingly, the 
pyridine-containing analogues 1b and 1c show higher relative 
Vmax values than that of 1a. Considering the observed cmax, lBL, 
and Vmax values, 1c was concluded to be the most suitable 
compound for cellular and animal imaging among 1b–d. In fact, 
1c exhibits a higher NIR bioluminescence intensity than that of 
LH2 at low concentration in cellular imaging of LLC/luc, being 
similar to that of 1a-HCl. In the case of in vivo imaging of lung 
metastases located deep in the mouse bodies, the 
bioluminescence intensity of 1c is six-fold higher than that of 
LH2 and is equivalent to that of 1a-HCl. These experimental 
data demonstrate that 1c is of practical use for in vivo optical 
imaging of deep tissues. 
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Graphical Abstract 
 
< Synthesis and luminescence properties of near-infrared N-heterocyclic luciferin analogues for in vivo optical imaging > 
 
< Ryohei Saito, Takahiro Kuchimaru, Shoko Higashi, Shijia W. Lu, Masahiro Kiyama, Satoshi Iwano, Rika Obata, Takashi 
Hirano, Shinae Kizaka-Kondoh,* and Shojiro A. Maki*> 
 
<Summary> 
N-Heterocyclic derivatives (1b–d) of the near-infrared luciferin analogue, AkaLumine (1a) were synthesized. Among 1b–d, 1c 
(named as “seMpai”) had higher solubility in PBS than 1a and showed the same bioluminescence maximum as 1a. In in vivo imaging 
experiments with mice, seMpai exhibited similar bioluminescence intensity to 1a, supporting the usefulness of seMpai for 
near-infrared bioluminescence imaging of deep tissues. 
<Diagram> 
 
 
